We are live on ! Find out more
SBIO icon

ALPS Medical Breakthroughs ETF

41 hedge funds and large institutions have $44.3M invested in ALPS Medical Breakthroughs ETF in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,200% more call options, than puts

Call options by funds: $874K | Put options by funds: $38K

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

14% more capital invested

Capital invested by funds: $38.8M → $44.3M (+$5.53M)

5% more funds holding

Funds holding: 3941 (+2)

0.37% more ownership

Funds ownership: 40.82%41.19% (+0.37%)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

Holders
41
Holders Change
+2
Holders Change %
+5.13%
% of All Funds
0.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
8
Reduced
10
Closed
7
Calls
$874K
Puts
$38K
Net Calls
+$836K
Net Calls Change
+$689K
Name Holding Trade Value Shares
Change
Change in
Stake
DC
1
Davenport & Co
Virginia
$21.8M +$66.4K +2,137 +0.3%
Morgan Stanley
2
Morgan Stanley
New York
$4.51M +$893K +28,741 +25%
Bank of America
3
Bank of America
North Carolina
$3.98M -$130K -4,182 -3%
UBS Group
4
UBS Group
Switzerland
$2.62M -$238K -7,668 -8%
RJFSA
5
Raymond James Financial Services Advisors
Florida
$2.09M -$218K -7,032 -10%
SFS
6
Strategic Financial Services
New York
$1.63M -$28.3K -910 -2%
NAM
7
NTV Asset Management
West Virginia
$1.53M -$9.32K -300 -0.6%
Wells Fargo
8
Wells Fargo
California
$1.13M +$581K +18,694 +109%
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$681K +$48.3K +1,556 +8%
LPL Financial
10
LPL Financial
California
$655K -$98.8K -3,180 -13%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$434K -$220K -7,097 -34%
KAS
12
Kestra Advisory Services
Texas
$385K
EWA
13
Exencial Wealth Advisors
Oklahoma
$384K -$19.6K -630 -5%
JIP
14
Jaffetilchin Investment Partners
Florida
$366K +$360K +11,599 New
GS
15
GTS Securities
New York
$330K +$325K +10,452 New
PWA
16
Phoenix Wealth Advisors
North Carolina
$302K -$14.3K -460 -5%
Citadel Advisors
17
Citadel Advisors
Florida
$294K +$145K +4,675 +101%
Cambridge Investment Research Advisors
18
Cambridge Investment Research Advisors
Iowa
$286K +$11.9K +382 +4%
RPCONE
19
Retirement Planning Company of New England
Rhode Island
$259K +$5.25K +169 +2%
RJA
20
Raymond James & Associates
Florida
$213K +$210K +6,757 New
AWM
21
AllSquare Wealth Management
New York
$98.5K
Osaic Holdings
22
Osaic Holdings
Arizona
$86.9K -$13.9K -447 -14%
NCM
23
Northwest Capital Management
Oregon
$44.2K +$43.5K +1,400 New
Carson Wealth (CWM LLC)
24
Carson Wealth (CWM LLC)
Nebraska
$44K +$43.5K +1,400 New
US Bancorp
25
US Bancorp
Minnesota
$31.6K

SBIO Hedge Fund Activity: Q2 2023 in Review

41 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ALPS Medical Breakthroughs ETF (SBIO) for Q2 2023, worth a combined $44.3M — up 14% from $38.8M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SBIO positions and 7 closed out — a net gain of 2 holders — while 8 added to existing stakes and 10 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $893K. The largest seller was Beacon Pointe Advisors, exiting entirely with an estimated $853K sold.

  • 41 institutional investors held ALPS Medical Breakthroughs ETF (SBIO) as of Q2 2023, up from 39 in Q1 2023.
  • Funds reported $44.3M of ALPS Medical Breakthroughs ETF stock for Q2 2023, up 14% quarter-over-quarter.
  • 9 funds opened new ALPS Medical Breakthroughs ETF positions in Q2 2023 and 7 closed out, a net change of +2 holders.
  • The largest ALPS Medical Breakthroughs ETF buyer in Q2 2023 was Morgan Stanley, an estimated $893K added.
  • The largest ALPS Medical Breakthroughs ETF seller in Q2 2023 was Beacon Pointe Advisors, an estimated $853K sold.

Based on aggregated 13F filings for Q2 2023.